In 2016, Xu et al. described a novel DLL4 antibody, MGZ01, which reduced the CD24−/CD44+ breast cancer CSC population and significantly attenuated tumor growth in MDA-MB-231 xenograft models [378]. This evidence concerns the gene CD44 and neoplasm.